Biliary tract cancers: current knowledge, clinical candidates and future challenges

Noor-Ul-Ain Tariq; Mairead Mcnamara; Juan Valle

doi:10.2147/cmar.s157092

Biliary tract cancers: current knowledge, clinical candidates and future challenges

Noor-Ul-Ain Tariq, Mairead Mcnamara, Juan Valle

Research output: Contribution to journal › Article › peer-review

Abstract

Biliary tract cancers (BTC) are rare with a poor prognosis. Due to the advent of genomic sequencing, new data has emerged regarding the molecular make up of this disease. To add to the complexity, the various subtypes also harbour a varied genetic composition. The commonly-mutated genes associated with this cancer are KRAS, EGFR, IDH, FGFR and BAP 1. Various clinical studies are looking at targeting these genetic mutations. Another therapeutic area of note is the potential for use of immunotherapy in patients with BTC. Although BTC may be a result of chronic inflammation, this does not necessarily translate into increased immunogenicity. This literature review discusses the diverse molecular and immune-related pathways in patients with BTC and their potential therapeutic implications.

Original language	English
Pages (from-to)	2623-2642
Number of pages	20
Journal	Cancer Management and Research
Volume	2019
Issue number	11
Early online date	29 Mar 2019
DOIs	https://doi.org/10.2147/cmar.s157092
Publication status	Published - 2019

Keywords

Biliary tract cancer
intrahepatic cholangiocarcinoma
extrahepatic cholangiocarcinoma
gallbladder cancer
genome sequencing
molecular targets
immunotherapy

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/cmar.s157092Licence: CC BY-NC

Cite this

@article{d6a16bcb01d84d4bb17ed70b485fd60d,

title = "Biliary tract cancers: current knowledge, clinical candidates and future challenges",

abstract = "Biliary tract cancers (BTC) are rare with a poor prognosis. Due to the advent of genomic sequencing, new data has emerged regarding the molecular make up of this disease. To add to the complexity, the various subtypes also harbour a varied genetic composition. The commonly-mutated genes associated with this cancer are KRAS, EGFR, IDH, FGFR and BAP 1. Various clinical studies are looking at targeting these genetic mutations. Another therapeutic area of note is the potential for use of immunotherapy in patients with BTC. Although BTC may be a result of chronic inflammation, this does not necessarily translate into increased immunogenicity. This literature review discusses the diverse molecular and immune-related pathways in patients with BTC and their potential therapeutic implications.",

keywords = "Biliary tract cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, genome sequencing, molecular targets, immunotherapy",

author = "Noor-Ul-Ain Tariq and Mairead Mcnamara and Juan Valle",

year = "2019",

doi = "10.2147/cmar.s157092",

language = "English",

volume = "2019",

pages = "2623--2642",

journal = "Cancer Management and Research",

issn = "1179-1322",

publisher = "Dove Medical Press ",

number = "11",

}

TY - JOUR

T1 - Biliary tract cancers: current knowledge, clinical candidates and future challenges

AU - Tariq, Noor-Ul-Ain

AU - Mcnamara, Mairead

AU - Valle, Juan

PY - 2019

Y1 - 2019

N2 - Biliary tract cancers (BTC) are rare with a poor prognosis. Due to the advent of genomic sequencing, new data has emerged regarding the molecular make up of this disease. To add to the complexity, the various subtypes also harbour a varied genetic composition. The commonly-mutated genes associated with this cancer are KRAS, EGFR, IDH, FGFR and BAP 1. Various clinical studies are looking at targeting these genetic mutations. Another therapeutic area of note is the potential for use of immunotherapy in patients with BTC. Although BTC may be a result of chronic inflammation, this does not necessarily translate into increased immunogenicity. This literature review discusses the diverse molecular and immune-related pathways in patients with BTC and their potential therapeutic implications.

AB - Biliary tract cancers (BTC) are rare with a poor prognosis. Due to the advent of genomic sequencing, new data has emerged regarding the molecular make up of this disease. To add to the complexity, the various subtypes also harbour a varied genetic composition. The commonly-mutated genes associated with this cancer are KRAS, EGFR, IDH, FGFR and BAP 1. Various clinical studies are looking at targeting these genetic mutations. Another therapeutic area of note is the potential for use of immunotherapy in patients with BTC. Although BTC may be a result of chronic inflammation, this does not necessarily translate into increased immunogenicity. This literature review discusses the diverse molecular and immune-related pathways in patients with BTC and their potential therapeutic implications.

KW - Biliary tract cancer

KW - intrahepatic cholangiocarcinoma

KW - extrahepatic cholangiocarcinoma

KW - gallbladder cancer

KW - genome sequencing

KW - molecular targets

KW - immunotherapy

U2 - 10.2147/cmar.s157092

DO - 10.2147/cmar.s157092

M3 - Article

SN - 1179-1322

VL - 2019

SP - 2623

EP - 2642

JO - Cancer Management and Research

JF - Cancer Management and Research

IS - 11

ER -

Biliary tract cancers: current knowledge, clinical candidates and future challenges

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this